Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HINT1 | P49773 | 4/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831524 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL412371 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL14143259 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL14440994 | 0.96 | HPGD (0.63) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL1738417 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL1738416 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL1738418 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL26208536 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL16317882 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL12031280 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002737-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CUREVAC AG (DE) | 2022-01-06 | — | — | US | claimed |
| EP-1660057-B1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | OPHTHOTECH CORP (US) | 2012-05-23 | — | — | EP | claimed |
| EP-2281885-A1 | Combination therapy for the treatment of ocular neovascular disorders | Ophthotech Corporation (US) | 2011-02-09 | — | — | EP | claimed |
| US-20070021327-A1 | Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor | GILEAD SCIENCES, INC. (US) | 2007-01-25 | — | — | US | claimed |
| US-12016875-B2 | Methods for treating or preventing ophthalmological conditions | IVERIC BIO, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240182894-A1 | COMPOSITIONS AND METHODS FOR MODULATING SOS GENE EXPRESSIONS | MOLECULAR AXIOM, LLC | 2024-06-06 | — | — | US | disclosed |
| EP-4374873-A2 | METHODS FOR TREATING OR PREVENTING OPTHALMOLOGICAL CONDITIONS | IVERIC bio, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024100247-A1 | ARTIFICIAL NUCLEIC ACIDS FOR SITE-DIRECTED EDITING OF A TARGET RNA | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2024-05-16 | — | — | WO | disclosed |
| US-20240141346-A1 | TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES | MIRECULE INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11946050-B2 | Polynucleotide compositions and methods for gene expression regulations | APTAH BIO, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240101608-A1 | OPTIMIZED NUCLEIC ACID MOLECULES | CureVac SE (DE) | 2024-03-28 | — | — | US | disclosed |
| US-20230399649-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES | CureVac SE (DE) | 2023-12-14 | — | — | US | disclosed |
| WO-2009030481-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
| EP-0828849-B1 | HIGH-AFFINITY OLIGONUCLEOTIDE LIGANDS TO PDGF | GILEAD SCIENCES INC (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-0828849-A4 | HIGH-AFFINITY OLIGONUCLEOTIDE LIGANDS TO GROWTH FACTORS | GILEAD SCIENCES INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1042348-A4 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1042348-A1 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031119-A1 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0828849-A1 | HIGH-AFFINITY OLIGONUCLEOTIDE LIGANDS TO GROWTH FACTORS | NeXstar Pharmaceuticals, Inc. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038579-A1 | HIGH-AFFINITY OLIGONUCLEOTIDE LIGANDS TO GROWTH FACTORS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399649-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES | PABPC4, L3MBTL4, NSUN3 | HPGD 4474/4885HINT1 1076/4885NT5E 385/4885 |
| US-20220002737-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CPSF6, CPSF1, RNMT | HPGD 4528/4885HINT1 1825/4885NT5E 234/4885 |
| US-12016875-B2 | Methods for treating or preventing ophthalmological conditions | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885NT5E 75/4885 |
| US-20240101608-A1 | OPTIMIZED NUCLEIC ACID MOLECULES | CPSF1, HNRNPAB, SPPL2A | HPGD 4106/4885HINT1 1700/4885NT5E 765/4885 |
| US-20240141346-A1 | TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES | RNASE1, DCLRE1B, CD2BP2 | HPGD 4476/4885HINT1 3019/4885NT5E 723/4885 |
| US-20070021327-A1 | Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor | FIBP, PDGFA, PDGFRA | HPGD 4318/4885HINT1 3338/4885NT5E 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.